OrbiMed Analysis
What is OrbiMed?
Global healthcare investment firm with $19B AUM
Location
601 Lexington Avenue, New York, New York 10022, United States
Employees
51-200
Founded
1989
Product Features & Capabilities
- Investment in biopharmaceuticals
- Financing for medical devices
- Support for digital health innovations
- Investment in diagnostics
- Funding for healthcare services
Investment Focus
OrbiMed Advisors primarily focuses on investing in the global healthcare industry, targeting sectors such as biopharmaceuticals, medical devices, diagnostics, and healthcare services. Their investment strategy encompasses three main areas: public equity, private equity, and private credit/royalty. They engage in various stages of investment, ranging from seed-stage venture capital to investments in large publicly-traded companies.
Assets Under Management
$17 billion
Investment Geography
OrbiMed Advisors primarily invests globally, with a focus on key healthcare markets in North America, Europe, and Asia.
Key Portfolio Companies
- AbCellera - Engages in partnerships to discover and develop next-generation therapeutic antibodies using a single-cell platform that integrates various advanced technologies.
- ACELYRIN - A biopharma company focused on providing life-changing treatment options by identifying and accelerating the development of promising drug candidates, particularly in immunology.
- Acutus - Develops a novel electro-anatomical mapping catheter for atrial fibrillation ablation procedures, integrating ultrasound technology for real-time imaging.
- Adaptive Biotechnologies - A biotechnology company focused on harnessing the adaptive immune system to transform disease diagnosis and treatment.
- ADARx Pharmaceuticals - Developing a proprietary RNA targeting platform for treating various diseases, including genetic and central nervous system disorders.
- Adcendo - A clinical-stage company developing first-in-class antibody-drug conjugates (ADCs) for cancer treatment, targeting tissue factor with minimized bleeding risk.
- Adela - Focused on cancer detection through a routine blood test using genome-wide methylation analysis technology.
- Aerin Medical - Develops non-invasive procedures for chronic nasal airway conditions, utilizing temperature-controlled technology for symptom improvement.
- AIMS - A multi-specialty hospital chain in North India, expanding its presence in East India.
- AK Medical - A leader in joint replacement products in China, pioneering the use of 3D printing technology in orthopedic products.
Notable Exits
- BioAge Labs - A clinical-stage biotechnology company focused on developing therapeutics for obesity and metabolic diseases.
- Humacyte - Specializes in products for vascular diseases and the replacement of anatomical conduits.
- XtalPi - A pharmaceutical technology company that innovates drug discovery through dry lab predictions validated by wet lab results. The specific exit methods for these companies were not detailed in the sources.
Recent Fundraising
$4.3B
Management Team
The management team of OrbiMed Advisors includes the following members:
- **Sven H. Borho, CFA**
- **Carl L. Gordon, Ph.D., CFA**
- **W. Carter Neild, CFA**
- **Geoffrey C. Hsu, CFA**
- **C. Scotland Stevens**
- **David Bonita, M.D.**
- **Matthew Rizzo**
- **Samuel Isaly** (CEO)
- **Michael Sheffery**
- **Arvind Desai**
- **Trey Block**
- **Alexander**
Other Considerations
$19 billion in assets under management; Over 500 portfolio companies; 130+ professionals in the team; 12 global locations; 130+ venture-backed IPOs
